Spots Global Cancer Trial Database for Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Topotecan
Official Title: A Phase I, Open-Label, Study of the Safety and Tolerability of KU-0059436 and Topotecan in the Treatment of Patients With Advanced Solid Tumours
Study ID: NCT00516438
Conditions
Study Description
Brief Summary: The purpose of this study is to identify a safe and tolerable dose of the drug KU-0059436 that can be given in combination with topotecan chemotherapy in patients with advanced solid tumours
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Glasgow, , United Kingdom
Research Site, Leicester, , United Kingdom
Research Site, Manchester, , United Kingdom
Contact Details
Name: James Cassidy
Affiliation: Beaston Oncology Centre, Glasgow, UK
Role: PRINCIPAL_INVESTIGATOR
Name: James Carmichael, BSc MBChB MD FRCP
Affiliation: KuDOS Pharmaceutical Ltd
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
